.png)
WoundClot (Core Scientific Creations)
Cellulose hemostatic trauma gauze for point-of-injury bleeding control (WoundClot)
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Core Scientific Creations is positioned as a focused dual-use medtech manufacturer with WoundClot as its flagship product, emphasizing bleeding control across trauma, surgical, and prehospital markets. The company appears to be expanding through distribution partnerships and regulated-market access rather than broad product diversification.
Efficiency Ratio
The company appears to achieve strong market reach from a relatively small footprint, but public visibility of revenue, hiring, and operating scale is limited, suggesting moderate-to-strong output efficiency with constrained transparency.
Evidence Signals
Strategic distribution agreement announced with Getz Healthcare for Australia and New Zealand availability of WoundClot Hemostatic Gauze.
Sinai Holdings LLC announced an investment into WoundClot / Core Scientific Creations.
WoundClot Hemostatic Gauze is listed in FDA commercial distribution records as a prehospital hemostatic gauze device.
Company reports CE-marked and FDA-cleared/regulated hemostatic gauze product positioning for trauma and surgical use.
LinkedIn profile shows multiple operating locations in Israel, the United States, and India, indicating an international operating footprint.
Company states WoundClot is manufactured in Petah Tikva and used by European hospitals and American and Israeli first responders.
Public materials describe a cellulose-based 3D gel matrix that absorbs up to 2,500% of its weight in blood and remains active for up to 24 hours.
- About
- Israeli hemostatics company — legal entity Core Scientific Creations Ltd. (Petah Tikva; founded 2012; founder/CEO Yuval Yaskil; US arm Core Scientific North America, Inc.), known worldwide by its product brand WoundClot. WoundClot hemostatic gauze is the world's only Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) hemostatic: engineered cellulose that is inherently hemostatic with no impregnated active agent — on blood contact it converts from dry gauze into a tenacious, adhesive 3D gel matrix that absorbs up to ~2,500% of its weight, controls capillary, venous and arterial bleeding non-compressionally, and remains effective up to 24 hours, including in coagulopathic or anticoagulated patients. The surgical line is a CE Class III implantable, bioabsorbable device with the fastest resorption profile available (~7-14 days). FDA-cleared (510(k) K160679, 2016) and CE-marked; distributed in 32 countries; adopted by Israeli police forces after the 2016 attacks and deployed during October 2023. Explicitly built for pre-hospital civilian and military hemorrhaging trauma — a pure-play point-of-injury hemorrhage-control ('stop the bleed' / TCCC) fit, used by military medics, EMS and surgeons (cardiovascular/orthopedic/ENT).
- Tags
- #hemostatic #bleedingcontrol #gauze #trauma #tccc #stopthebleed #cellulose #fda #ce #military #dualuse